# Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

> **NCT07218783** · PHASE3 · RECRUITING · sponsor: **SpyGlass Pharma, Inc.** · enrollment: 400 (estimated)

## Conditions studied

- Cataract
- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost Implant System
- **DEVICE:** SpyGlass IOL
- **DRUG:** Timolol Maleate Ophthalmic Solution, 0.5%
- **DEVICE:** Commercial IOL

## Key facts

- **NCT ID:** NCT07218783
- **Lead sponsor:** SpyGlass Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2029-03-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218783, "Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07218783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*